Pds biotech reports third quarter 2022 financial results and provides business update

Florham park, n.j., nov. 14, 2022 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, will discuss its financial results for the quarter ended september 30, 2022 and provide a business update on its conference call today.
PDSB Ratings Summary
PDSB Quant Ranking